Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Amsterdam University Medical Centers · University of Amsterdam · +33 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
378
total citations
- FWCI
- 64.87
- Percentile
- 100%
- References
- 20
Citations per year
Authors
31Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Crohn's disease
- Internal medicine
- Population
- Clinical trial
- Randomized controlled trial
- Disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- GSGilead Sciences
- BBiogen
- CCelgene
- AAbbVie
- EPEA Pharma Co., Ltd.
- MMylan
- NPNichi-Iko Pharmaceutical
- CCelltrion
- KPKyorin Pharmaceutical
- STSeres Therapeutics
- DDaiichi-Sankyo
- TPTillotts Pharma
- MTMitsubishi Tanabe Pharma Corporation
- OPOno Pharmaceutical
- SPSun Pharma
- NNorgine
- GGenentech
- SSamsung
- AAllergan
- PJPfizer Japan
- UPUCB Pharma